Optimal VMAT techniques for adjuvant breast radiotherapy (n)over-tilde initial results of cooperative study from two institutes

被引：0
|
作者：
Topczewska-Bruns, J. [1 ]
Kawa-Iwanicka, A. [2 ]
Pancewicz-Janczuk, B. [3 ]
Polaczek-Grelik, K. [2 ]
Kokoszka, A. [4 ]
Kisielewska-Birycka, M. [3 ]
Filipowski, T. [1 ]
机构：
[1] Comprehens Canc Ctr, Dept Radiotherapy, Bialystok, Poland
[2] 2 NU MED Canc Diag & Treatment Ctr, Dept Phys, Katowice, Poland
[3] Comprehens Canc Ctr, Dept Phys, Bialystok, Poland
[4] 2 NU MED Canc Diag & Treatment Ctr, Dept Radiotherapy, Katowice, Poland
来源：
RADIOTHERAPY AND ONCOLOGY | 2015年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP-1584
引用
收藏
页码：S867 / S867
页数：1
相关论文
共 35 条
  • [21] Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy
    Maiorano, Eugenio
    Regan, Meredith M.
    Viale, Giuseppe
    Mastropasqua, Mauro G.
    Colleoni, Marco
    Castiglione-Gertsch, Monica
    Price, Karen N.
    Gelber, Richard D.
    Goldhirsch, Aron
    Coates, Alan S.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) : 211 - 218
  • [22] Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy
    Eugenio Maiorano
    Meredith M. Regan
    Giuseppe Viale
    Mauro G. Mastropasqua
    Marco Colleoni
    Monica Castiglione-Gertsch
    Karen N. Price
    Richard D. Gelber
    Aron Goldhirsch
    Alan S. Coates
    Breast Cancer Research and Treatment, 2010, 121 : 211 - 218
  • [23] Prevention of anastrozole induced bone loss with monthly oral ibandronate during adjuvant breast cancer therapy: Two year results from the AIRIBON study
    Lester, James
    Dodwell, David
    Purohit, Omprakash
    Gutcher, Sandra
    Ellis, Sue
    Thorpe, Ruth
    Horsman, Janet
    Brown, Janet
    Hannon, Rosemary
    Coleman, Robert
    CANCER TREATMENT REVIEWS, 2008, 34 : S51 - S51
  • [24] Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: First long time results from a clinical study
    Johansson, Bengt
    Karlsson, Leif
    Liljegren, Goran
    Hardell, Lennart
    Persliden, Jan
    RADIOTHERAPY AND ONCOLOGY, 2009, 90 (01) : 30 - 35
  • [25] Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: results from the phase III Success A study
    Friedl, T. W. P.
    Rack, B.
    Fehm, T.
    Mueller, V.
    Lichtenegger, W.
    Blohmer, J. -U.
    Lorenz, R.
    Forstbauer, H.
    Bauer, E.
    Fink, V.
    Bekes, I.
    Jueckstock, J.
    Schneeweiss, A.
    Tesch, H.
    Mahner, S.
    Brucker, S. Y.
    Heinrich, G.
    Beckmann, M.
    Coleman, R.
    Janni, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 32 - 32
  • [26] Radiotherapy concurrent with trastuzumab is well tolerated in the adjuvant treatment of women with HER2-positlve breast cancer: cardiac safety data from the NCCTG N9831 study
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 113 - 113
  • [27] Importance of HER2 and receptor status on the response to adjuvant radiotherapy in high-risk breast cancer - Results from the DBCG82 b&c randomized study
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 112 - 112
  • [28] Use of monthly oral ibandronate to prevent anastrozole-induced bone loss during adjuvant treatment for breast cancer: Two-year results from the ARIBON study
    Lester, J.
    Dodwell, D.
    Purohit, O. P.
    Gutcher, S. A.
    Ellis, S. P.
    Thorpe, R.
    Horsman, J. M.
    Brown, J. E.
    Hannon, R. A.
    Coleman, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [29] Postoperative adjuvant randomised trial comparing chemo-endocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon cooperative study group of adjuvant chemo-endocrine therapy for breast cancer (ACETBC) of Japan (vol 32, pg 235, 1996)
    Morimoto
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (07) : 1264 - 1264
  • [30] Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study
    Janni, Wolfgang
    Friedl, Thomas W. P.
    Fehm, Tanja
    Mueller, Volkmar
    Lichtenegger, Werner
    Blohmer, Jens
    Lorenz, Ralf
    Forstbauer, Helmut
    Bauer, Emanuel
    Fink, Visnja
    Bekes, Inga
    Juckstock, Julia
    Schneeweiss, Andreas
    Tesch, Hans
    Mahner, Sven
    Brucker, Sara Y.
    Heinrich, Georg
    Beckmann, Matthias W.
    Coleman, Robert
    Rack, Brigitte
    CANCER RESEARCH, 2018, 78 (04)
1234